On July 28, 2021, Ihang Capital, the People's Government of Jiaojiang District, Taizhou City, and listed company Lingkang Pharmaceuticals (603669.SH) jointly initiated the establishment of a 500 million yuan MAH industry fund. The MAH project jointly set up by the three parties focuses on the whole industry chain services such as CRO R&D services, drug licensed management services, CMO management of raw platform production, drug listing and sales and customer services. Through the fund investment to attract a number of MAH projects, CRO projects, R & D team settled in the local, and around the high-end generic drugs + improved new drugs + innovative new drugs to create a pharmaceutical innovation plateau, to help the local pharmaceutical industry to form a rapid leapfrog development!
language
